Process Development and Synthesis of Process-Related Impurities of an Efficient Scale-Up Preparation of 5,2'-Dibromo-2,4',5'-Trihydroxy Diphenylmethanone as a New Acute Pyelonephritis Candidate Drug

• Published in: Molecules (Basel, Switzerland) Vol. 25; no. 3; p. 468
• Main Authors: Feng, Xiu E, Cui, Ke Meng, Li, Qing Shan, Wu, Zi Cheng, Lei, Fei
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 22.01.2020; MDPI
• Subjects: 5,2′-dibromo-2,4′,5′-trihydroxydiphenylmethanone; acute pyelonephritis; Chloride; Chromatography; Drug dosages; Drug resistance; High performance liquid chromatography; Impurities; Laboratories; Liquid chromatography; polymorph; process development; process-related impurity; Pyelonephritis; Quality control; R&D; Reagents; Research & development; acute pyelonephritis; 5,2′-dibromo-2,4′,5′-trihydroxydiphenylmethanone; process-related impurity; process development; polymorph
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules25030468

Based on a foregoing gram-scale laboratory process, an efficient scale-up preparation process of 5,2'-dibromo-2,4',5'-trihydroxydiphenylmethanone ( ), a new acute pyelonephritis candidate drug, was developed and validated aiming to reduce by-products and achieve better impurity profiles. Meanwhile, the polymorph of and process-related impurities were also investigated. Ultimately, the optimal reaction conditions were verified by evaluating the impurity profiles and their formation during the synthesis. Six process-related impurities were synthesized and identified, being useful for the quality control of . Its finalized preparation process was further validated at 329-410 g scale-up production in 53.4-57.1% overall yield with 99.95-99.98% high-performance liquid chromatography (HPLC) purity, and it is currently viable for commercial production. and were identified as the main single impurities in , with the content controlled to be less than 0.03%.